

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**China Regenerative Medicine International Limited**  
**中國再生醫學國際有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 8158)**

**CLARIFICATION ANNOUNCEMENT**

Reference is made to (i) the announcement of China Regenerative Medicine International Limited (the “**Company**”) dated 10 April 2023 in relation to the final results of the Company for the year ended 31 December 2022 (the “**Results Announcement**”); and (ii) the annual report of the Company for the year ended 31 December 2022 (the “**Annual Report**”). Unless otherwise defined herein, capitalised terms used in this announcement shall have the same meanings as those defined in the Results Announcement and the Annual Report.

The Company would like to make the following clarification to the information disclosed in the Results Announcement and the Annual Report as follows:

- 1) the section headed “Allowance for expected credit losses assessment of trade and other receivables” of “Independent Auditor’s Report” in page 105 of the annual report contained in the Results Announcement and would like to clarify that the “Provision for allowance for expected credit losses of other receivables approximately HK\$7,276,000” on the second paragraph should have been stated as “Provision for allowance for expected credit losses of other receivables approximately HK\$25,402,000”;
- 2) the section headed “Provision for expected credit losses of trade and other receivables” of “Critical Accounting Estimates and Judgements” in page 152 of the annual report contained in the Results Announcement and would like to clarify that the “Provision for allowance for expected credit losses of other receivables approximately HK\$7,276,000” on the second paragraph should have been stated as “Provision for allowance for expected credit losses of other receivables approximately HK\$25,402,000”; and

3) the section headed “Credit Risk” of “Financial Risk Management” in page 193 of the Annual Report contained in the Results Announcement should be:

	2022			2021		
	Weighted average lifetime ECLs %	Gross carrying amount HK\$'000	Lifetime ECLs HK\$'000	Weighted average lifetime ECLs %	Gross carrying amount HK\$'000	Lifetime ECLs HK\$'000
Other receivables	4	228,194	9,964	2	145,793	2,688
Stated as:						
Other receivables and refundable deposit	9	269,732	25,402	8	224,631	18,126

Save as disclosed in the announcement, all information set out in the Results Announcement and the annual report remain unchanged.

By Order of the Board  
**China Regenerative Medicine International Limited**  
**Wang Chuang**  
*Chairman, Chief Executive Officer and Executive Director*

Hong Kong, 11 April 2023

*As at the date of this announcement, the executive Director is Mr. Wang Chuang (Chairman and Chief Executive Officer); the non-executive Director is Mr. Tsang Ho Yin; and the independent non-executive Directors are Ms. Huo Chunyu, Dr. Liu Ming and Mr. Leung Man Fai.*

*This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.*

*This announcement will remain on the “Latest Listed Company Information” page of the website of the Stock Exchange at [www.hkexnews.hk](http://www.hkexnews.hk) for at least seven days from the date of its publication. This announcement will also be published on the Company’s website at [www.crmi.hk](http://www.crmi.hk).*